<p>Swiss Webster mice were infected i.p. with 5x10<sup>3</sup> tachyzoites of <i>T</i>. <i>gondii</i> (RH strain) one day prior to the start of treatment. Results were evaluated by the Kaplan-Meier product limit method, and compared using the log-rank (Mantel-Cox) test. * <i>P</i><0.05 vs. untreated controls. The numbers of treated mice in each group were: untreated, 10 (A), 14 (B and D) and 15 (C); 50 and 100 mg Cipro, 11 (three groups each); 150 mg Cipro, 8 (two groups); 50 and 100 mg Et-Cipro, 11 (three groups); 50 and 100 mg Ph-Cipro, 8 (two groups); 150 mg Ph-Cipro, 11 (three groups); 50 mg Adam-Cipro, 3 (one group); 100 mg Adam-Cipro, 12 (three groups).</p
<div><p>Toxoplasmosis, caused by the protozoan <i>Toxoplasma gondii</i>, is a worldwide disease whos...
<p>The 96-h survival rate of the cefotaxime-plus-ciprofloxacin group (85%, 17/20) was significantly ...
<p>Mice were nasally immunised with rTgACT or PBS. Two weeks after the last immunisation, mice were ...
<div><p><b><i>gondii</i></b>. </p> <p>Survival of naïve mice treated with PBS (open square, n=8); un...
<p><b><i>A</i></b><b>,</b> Atorvastatin treatment of mice infected with the RH strain. 20 RH tachyzo...
<p>Mice were intraperitoneally administrated with <i>P</i>. <i>betle</i> extracts at 25, 100 and 400...
<p>Mice received 9.25/or 15% TBSA wounding to establish following four treatment groups: CI, RI, Wou...
<p>(A) Tachyzoites of <i>T</i>. <i>gondii</i> were treated with Cipro derivatives for 6 h, from 1–7 ...
<p>The mice were nasally immunized with rTgROP17 or GST control. Two weeks after the final immunizat...
<p>To assess differences among survival curves, a log-rank test of Kaplan–Meier was performed, which...
<p>(A) Survival and (B) parasitemia curves in <i>P</i>. <i>berghei</i> ANKA-infected mice treated wi...
<p>Two groups of mice (16 mice per group) were immunised with 30 μg of rTgPDI or PBS through intrana...
<p>Mice were monitored for survival. Survival data are plotted on a Kaplan-Meier curve (A). Treatmen...
<p>Immunofluorescence microscopy of LLC-MK<sub>2</sub> cells infected with tachyzoites of <i>T</i>. ...
The usefulness of scid mice bearing endogenous Pneumocystis carinii infection as a model for experim...
<div><p>Toxoplasmosis, caused by the protozoan <i>Toxoplasma gondii</i>, is a worldwide disease whos...
<p>The 96-h survival rate of the cefotaxime-plus-ciprofloxacin group (85%, 17/20) was significantly ...
<p>Mice were nasally immunised with rTgACT or PBS. Two weeks after the last immunisation, mice were ...
<div><p><b><i>gondii</i></b>. </p> <p>Survival of naïve mice treated with PBS (open square, n=8); un...
<p><b><i>A</i></b><b>,</b> Atorvastatin treatment of mice infected with the RH strain. 20 RH tachyzo...
<p>Mice were intraperitoneally administrated with <i>P</i>. <i>betle</i> extracts at 25, 100 and 400...
<p>Mice received 9.25/or 15% TBSA wounding to establish following four treatment groups: CI, RI, Wou...
<p>(A) Tachyzoites of <i>T</i>. <i>gondii</i> were treated with Cipro derivatives for 6 h, from 1–7 ...
<p>The mice were nasally immunized with rTgROP17 or GST control. Two weeks after the final immunizat...
<p>To assess differences among survival curves, a log-rank test of Kaplan–Meier was performed, which...
<p>(A) Survival and (B) parasitemia curves in <i>P</i>. <i>berghei</i> ANKA-infected mice treated wi...
<p>Two groups of mice (16 mice per group) were immunised with 30 μg of rTgPDI or PBS through intrana...
<p>Mice were monitored for survival. Survival data are plotted on a Kaplan-Meier curve (A). Treatmen...
<p>Immunofluorescence microscopy of LLC-MK<sub>2</sub> cells infected with tachyzoites of <i>T</i>. ...
The usefulness of scid mice bearing endogenous Pneumocystis carinii infection as a model for experim...
<div><p>Toxoplasmosis, caused by the protozoan <i>Toxoplasma gondii</i>, is a worldwide disease whos...
<p>The 96-h survival rate of the cefotaxime-plus-ciprofloxacin group (85%, 17/20) was significantly ...
<p>Mice were nasally immunised with rTgACT or PBS. Two weeks after the last immunisation, mice were ...